Cell Therapy

Switch

Homepage

facebook

Other Hospital CMUH APP icon

CMUH App

Research & Innovation

:::

home/

Research & Innovation/

Regenerative Medicine/

Cell Therapy

Research & Innovation

Cell Therapy

On June 18, 2019, we established the cell therapy center in China Medical University

Hospital to promote clinical services related to the Regulations of special Medical Techniques, and actively develop and launch a number of multi-center clinical trials related to cell therapy. The clinical service operation of this cell therapy center has always been the learning object of many domestic medical institutions, and the R&D team is constantly innovating and actively conducting multi-center clinical trials of Phase I or Phase II, in order to solve the unmet clinical needs. In addition, we have also set up the international collaboration with Prof. Tseng in Harvard University, Boston for BAT men, Prof. Kawamoto in Kyoto for iPS-TCRT, and Prof. Wang in Melbourne for PD-1/TK iPS to develop advanced cell therapy for both cancer and regenerative medicine.

Main Product

DC cell therapy

Product Introduction

The principle of DC cell therapy is to utilize the characteristics of DC cells and antigens of cancer cells.

First of all, the operation takes out the tumor antigen culture, then separates the DC cells, makes a DC vaccine, injects into the cancer patient’s body, stimulates T lymph nodes, and suppresses the tumor.

Therefore, it has been recognized as a cancer treatment method.

DC細胞療法示意圖

Indications:：

Solid cancer stages I to III that are unresponsive to standard treatments:
First to second grade low-grade gliomas and third grade high-grade gliomas, liver cancer, epithelial ovarian cancer, pancreatic cancer, prostate cancer, head and neck cancer, breast cancer, colorectal cancer.
Stage 4 solid cancer:
Glioblastoma multiforme and subsequent brain tumors, liver cancer, epithelial ovarian cancer, pancreatic cancer, prostate cancer, head and neck cancer, breast cancer, lung cancer, and colorectal cancer.

Main Product

DC-CIK(WT1) cell therapy

Product Intro.

DC-CIK (WT1) cells are co-cultured with dendritic cells (DC) and cytokine-induced killer cells (CIK) in vitro for combined therapy of patients. In terms of the treatment mechanism, dendritic cells are professional antigen-presenting cells. Mature dendritic cells can present the tumor antigen of WT1 peptide through the MHC-I pathway, effectively resisting the immune evasion mechanism of tumor cells. Although CIK cells have It has extensive direct tumor-killing ability. However, through the co-culture of CIK cells and dendritic cells, CIK cells are further activated after the dendritic cells present the tumor antigen of WT1 peptide, thereby further strengthening the specific tumor-killing effect of CIK. .

DC-CIK(WT1) 細胞療法示意圖

Indications:：

Stage 4 solid cancer:
Breast cancer, colorectal cancer.

Main Product

CIK cell therapy

Product Intro.

CIK is a special immune cell group that is a combination of different cell populations of T cells, NK-T cells and NK cells. It is highly safe, has no restrictions on MHC (major histocompatibility complex) molecules and has anti-tumor activity. , can improve the immune system and enhance immunity, especially for patients after surgery or radiotherapy and chemotherapy. It can eliminate residual micro-metastatic lesions and prevent the spread and recurrence of cancer cells. Clinical studies have confirmed that CIK cells have significant efficacy when used in combination therapy with cancer drugs.

CIK細胞療法示意圖

Indications:：

Solid cancer stages I to III that are unresponsive to standard treatments:
Epithelial ovarian cancer, lung cancer, liver cancer, breast cancer, colorectal cancer, pancreatic cancer.
Stage 4 solid cancer:
Glioblastoma multiforme, epithelial ovarian cancer, lung cancer, liver cancer, breast cancer, colorectal cancer, pancreatic cancer, urothelial cell cancer.
Hematological malignancies: Hodgkin's lymphoma, B-cell non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, multiple myeloma.

Main Product

GDT cell therapy

Product Intro.

GDT cells are T lymphocytes with similar innate immunity. They are characterized by T cell receptors composed of gamma and delta chains. They are widely distributed in peripheral blood and mucosal tissues. They can quickly identify pathogens and further initiate adaptive immunity. They are The first line of immune defense. Activated GDT cells have diverse abilities, including the ability to eliminate infected cells or tumor cells, produce cytokines and chemokines, antigen presentation and regulatory capabilities. Therefore, GDT cells are useful for controlling human infections, allergies, autoimmunity and cancer. The occurrence and process both play an important role. The results of multiple clinical studies have also confirmed that GDT cells are effective when used in combination with cancer drugs.